Nanotherapeutics for cardiovascular disease

Nanotherapies are emerging rapidly as options to treat cardiovascular disease. However, insufficient and heterogeneous delivery remain critical issues. Novel strategies to boost targeted delivery of systemically administered nanoparticles by optimizing the particle physical properties or using immune cells as carriers promise to increase nanotherapeutic effectiveness in cardiovascular and other inflammatory diseases.

Automated summary

Nanotherapies are rapidly developing as a treatment option for cardiovascular disease, but issues with delivery remain critical. New strategies such as optimizing particle properties or using immune cells as carriers show promise in enhancing targeted delivery and effectiveness in cardiovascular and other inflammatory diseases.